Jan.23 -- Vas Narasimhan, chief executive officer at Novartis, discusses demand for gene therapy, the company’s new medicine portfolio and generic drug unit, and commitment to sustainability. He speaks with Bloomberg’s Francine Lacqua at the World Economic Forum’s annual meeting in Davos, Switzerland on "Bloomberg Surveillance."
